Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer
Phase of Trial: Phase I
Latest Information Update: 02 Dec 2016
At a glance
- Drugs Everolimus (Primary)
- Indications Cancer
- Focus Pharmacodynamics; Pharmacogenomic
- 10 Jun 2017 Biomarkers information updated
- 25 Apr 2016 Status changed from active, no longer recruiting to discontinued.
- 20 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Feb 2016 as per ClinicalTrials.gov record.